Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China 2023-03-30 08:00
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients 2023-03-30 08:00
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063 2023-03-30 03:32
Broncus Medical (02216.HK) Announces Annual Results for 2022 2023-03-30 01:05
PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy 2023-03-29 22:53
bitBiome and Kaken Pharmaceuticals sign joint research agreement on the discovery of drugs for infectious diseases 2023-03-29 22:00
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer 2023-03-29 14:00
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia 2023-03-29 08:30
Innovent Announces 2022 Annual Results and Business Updates 2023-03-29 08:00
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China 2023-03-28 21:41
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation 2023-03-28 21:40
BIMINI HEALTH TECH ACQUIRES EXCLUSIVE LICENSE TO ACELLULAR DERMAL MATRIX PRODUCT PORTFOLIO 2023-03-28 21:20
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease 2023-03-28 20:11
Sirnaomics Announces 2022 Annual Results 2023-03-28 19:26
Tigermed Reports Full Year 2022 Results 2023-03-28 19:09
Seegene declares to share Syndromic PCR technologies to prevent future pandemics 2023-03-28 19:00
Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours 2023-03-28 19:00
OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab 2023-03-28 15:36
Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV 2023-03-28 13:00
Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors 2023-03-28 10:00
1 117 118 119 120 121 452